$GILD Company News Apple, Facebook pressured ahead of

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2014 at 10:47 AM

$GILD Company News

Apple, Facebook pressured ahead of earnings 18 min ago - Saumya Vaishampayan
U.S. stocks fall; PMI, home sales disappoint 22 min ago - Anora Mahmudova
U.S. stock futures pause after six-session win streak 8:57 a.m. Today - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. Today - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. Today - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Scouring the moonscape for leading stocks 3:01 p.m. April 22, 2014 - The Trading Deck
Centene shrugs off drug costs, Obamacare and beats profit views 2:42 p.m. April 22, 2014 - blogs.marketwatch.com
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs

Market Hustle: Stocks Weak After Tepid China, Drop in U.S. Home Sales 22 min ago - TheStreet.com
Stock Market News for April 23, 2014 - Market News 41 min ago - Zacks.com
Gilead (GILD) On Momo Momentum Watch Today 58 min ago - TheStreet.com
Big Biotech Is On The Move 9:47 a.m. Today - Seeking Alpha
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog 9:40 a.m. Today - Zacks.com
5 Stocks to Lose Post-Earnings - Analyst Blog 9:12 a.m. Today - Zacks.com
Gilead: X-Marks The Spot For Sovaldi Sales 9:05 a.m. Today - Seeking Alpha
Why Gilead Sciences (GILD) Stock Is Higher This Morning 9:01 a.m. Today - TheStreet.com
Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here 8:52 a.m. Today - Seeking Alpha
Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases 8:48 a.m. Today - Seeking Alpha
Morning Market Movers 8:44 a.m. Today - benzinga.com
Market Hustle: Stock Futures Turn Lower on Weak China Data; P&G Revenue Slips 8:35 a.m. Today - TheStreet.com
How Did Analysts Get Gilead's Earnings Completely Wrong? 8:19 a.m. Today - benzinga.com
5 Biotech Stocks Ready To Resume their Rally 8:16 a.m. Today - Barrons.com
UBS Top Stocks to Buy Working for Cancer Cures 7:52 a.m. Today - 247WallSt.com
Stock Futures Dip as Traders Eye Corporate Earnings 7:21 a.m. Today - FOXBusiness
Stocks Slip as Traders Review Earnings, Data 7:21 a.m. Today - FOXBusiness
Benzinga's Top #PreMarket Gainers 7:09 a.m. Today - benzinga.com
ETF Outlook For Wednesday, April 23, 2014 (MGC, IYZ, TAN, BBH, GILD, T) 6:41 a.m. Today - Benzinga.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha

Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam 2:24 p.m. April 14, 2014 - BusinessWire - BZX
Financial Release Dates -- Research on Gilead Sciences, Juniper Networks, FirstCommonwealth Financial, and Genuine Parts 9:00 a.m. April 14, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:24 a.m. April 12, 2014 - BusinessWire - BZX
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest 10:14 a.m. April 11, 2014 - PR Newswire - PRF
Today's Review on Active Stocks -- Research on Ashford Hospitality Trust, Dejour Energy, North American Palladium, and Gilead Sciences 1:30 p.m. April 10, 2014 - PR Newswire - PRF
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments 10:00 a.m. April 10, 2014 - PR Newswire - PRF
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C 1:02 a.m. April 10, 2014 - BusinessWire - BZX
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx 8:00 a.m. April 9, 2014 - PR Newswire - PRF
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection 8:31 a.m. April 7, 2014 - BusinessWire - BZX
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

Dr. David Lifschutz Honored for Psychiatry Innovation

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

New Podcast by Paralyzed Veterans of America Offers Unique Insights

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....

Rise Treatment Center Launches in Vegas for Teens

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...